Christopher C Chang, MD Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 1131 N 35th Ave Fl 2, Hollywood, FL 33021 Phone: 954-265-3030 Fax: 954-265-3065 |
Priya Ahya, AGACNP Allergy & Immunology Medicare: Medicare Enrolled Practice Location: 3700 Washington St Ste 200, Hollywood, FL 33021 Phone: 954-894-3003 Fax: 954-894-3323 |
Dr. Elias Salama, MD Allergy & Immunology Medicare: Not Enrolled in Medicare Practice Location: 1150 N 35th Ave, Suite 460, Hollywood, FL 33021 Phone: 954-981-9180 Fax: 954-961-4752 |
News Archive
Researchers from Cleveland Clinic's Wellness Institute and Harvard University have found that greater consumption of sugar-sweetened and low-calorie sodas is associated with a higher risk of stroke. Conversely, consumption of caffeinated or decaffeinated coffee was associated with a lower risk.
Adding more good news to last week's announcement that Nexavar (sorafenib) may be the first effective treatment for advanced liver cancer, researchers at the Lombardi Comprehensive Cancer Center at Georgetown University have uncovered a new molecular mechanism that may 'spontaneously' cause liver cancer.
Alexion Pharmaceuticals, Inc. today announced that the European Commission has granted an orphan drug designation (ODD) to Soliris (eculizumab), a first-in-class terminal complement inhibitor, for the prevention of graft rejection following solid organ transplantation. Graft rejection can cause severe injury to the transplanted organ and is a significant barrier to successful transplantation.
RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), announced that Pamela Pavco, Ph.D., Vice President of Pharmaceutical Development, will be presenting at the 3rd International Scar Club Meeting in Montpellier, France on March 26, 2010.
A research team led by Arun Iyer, Ph.D., assistant professor of pharmaceutical sciences in the Eugene Applebaum College of Pharmacy and Health Sciences at Wayne State University, has developed a nanoplatform technology that works in combination with existing chemotherapeutic drugs that may reverse drug-resistance in renal cell carcinoma.
› Verified 8 days ago